ArticleFrontiers in public health2026
Drug-resistant tuberculosis in Lishui, China: first-line drug resistance patterns, trends, and risk factors from a 10-year retrospective study (2015-2024).
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite ongoing global efforts, drug-resistant TB (DR-TB) continues to pose a substantial threat to public health, and systematic longitudinal surveillance data on local resistance patterns are lacking in many regions. This study analyzed first-line drug resistance patterns and annual trends in Lishui, China from 2015 to 2024 and identified independent risk factors for multidrug-resistant tuberculosis (MDR-TB). Methods: A total of 2,339 TB patients with available phenotypic drug susceptibility testing (pDST) results from the designated TB treatment institution in Lishui were retrospectively enrolled between January 2015 and December 2024. Annual drug resistance trends were assessed, and independent risk factors for MDR-TB were evaluated through multivariate logistic regression. Results: The overall prevalence of DR-TB and MDR-TB was 20.09 and 6.93%, respectively. Over the 10-year period, overall DR-TB prevalence declined from 23.50% in 2015 to 15.63% in 2024 (APC: -1.30%, Conclusion: The decrease in drug resistance among retreated patients was the main driver of the overall decline in DR-TB prevalence observed in Lishui across the study period. The relative stability of resistance in new patients suggests ongoing circulation of drug-resistant strains in the community, highlighting the need for expanded drug susceptibility testing (DST) coverage and strengthened community infection control. Enhanced treatment adherence and universal pDST coverage, particularly for retreated patients and socioeconomically vulnerable populations such as farmers, are essential for effective MDR-TB containment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.